Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Molecular Docking and Molecular Dynamic Effects of Omeprazole on CDKs 2, 4, and 6 as a Potential CDK Inhibitor in Cancer Treatment

Author(s): Navid Jamali, Roohollah Mohseni, Mansoor Zareei and Javad Saffari-Chaleshtori*

Volume 21, Issue 1, 2025

Published on: 18 January, 2024

Page: [110 - 117] Pages: 8

DOI: 10.2174/0115733947274344231116113325

Price: $65

Abstract

Introduction: Cyclin-dependent kinases (CDKs) are serine/threonine kinase proteins that regulate the cell cycle through phosphorylation and dephosphorylation. These proteins are a main target in cancer therapy. This study investigated the effect of omeprazole on CDK2, CDK4, and CDK6 through simulation studies.

Methods: To investigate the interaction between omeprazole and CDK2, 4, and 6, the threedimensional structure of omeprazole was obtained from PubChem, and the structures of CDK2, 4, and 6 were acquired from RCSB servers. The proteins were then simulated for 50 nanoseconds using the GROMACS 2021 platform before the docking process. Next, Autodock v.4.2.6 software was used to bind omeprazole as a ligand to these proteins, and a molecular dynamics simulation of the resulting protein-ligand complex was conducted using GROMACS after the docking process.

Results: Omeprazole exhibited a high affinity for interacting with CDK2, 4, and 6, mainly occurring in the ATP binding site of CDK4. However, the docking of omeprazole in the CDKs induced conformational changes in their structures, which could potentially affect their function and lead to cell cycle arrest.

Conclusion: Omeprazole, which is a proton pump inhibitor, can induce cell cycle arrest by interacting with the ATP-binding site of CDK4. Moreover, it can also induce conformational changes in CDK2, CDK4, and CDK6 through high-affinity interactions with specific amino acid residues.

Keywords: Cell cycle, cyclin-depending kinases, omeprazole, molecular dynamics, retinoblastoma protein, ATP.

« Previous Next »
Graphical Abstract

[1]
Liu F, Qu R, Yang L, Shi G, Hao S, Hu CJO, et al. Circular RNA controls tumor occurrence and development via cell cycle regulation. OncoTargets Ther 2022; 15: 993-1009.
[http://dx.doi.org/10.2147/OTT.S371629]
[2]
Gousias K, Theocharous T, Simon MJB. Mechanisms of cell cycle arrest and apoptosis in glioblastoma. Biomedicines 2022; 10(3): 564.
[http://dx.doi.org/10.3390/biomedicines10030564]
[3]
Schirripa A, Sexl V. Cyclin-dependent kinase inhibitors in malignant hematopoiesis. Front Oncol 2022; 12: 916682.
[4]
Sherr CJ, Roberts JMJG. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13(12): 1501-2.
[5]
Classon M, Harlow EJNRC. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 212: 910-7.
[http://dx.doi.org/10.1038/nrc950]
[6]
Roskoski R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res 2019; 139: 471-88.
[7]
Sanaei M. Effect of sodium butyrate on p16INK4a, p14ARF, p15INK4b, class I HDACs (HDACs 1, 2, 3) class II HDACs (HDACs 4, 5, 6), cell growth inhibition and apoptosis induction in pancreatic cancer AsPC-1 and colon cancer HCT-116 cell lines. Asian Pac J Cancer Prev 2022; 23(3): 795-802.
[8]
Panda M, Kalita E, Rao A. Mechanism of cell cycle regulation and cell proliferation during human viral infection. Adv Protein Chem Struct Biol 2023; 135: 497-525.
[9]
Ghelli Luserna di Rorà A, Jandoubi M, Martinelli G, Simonetti G. Targeting proliferation signals and the cell cycle machinery in acute leukemias: Novel molecules on the horizon. Molecules 2023; 28(3): 1224.
[http://dx.doi.org/10.3390/molecules28031224] [PMID: 36770891]
[10]
Garutti M, Targato G, Buriolla S, Palmero L, Minisini AM, Puglisi FJC. CDK4/6 inhibitors in melanoma: A comprehensive review. Cells 2021; 10(6): 1334.
[11]
Liu J-L, Ma H-P, Lu X-L, Sun S-H, Guo X. NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer. Int J Oncol 2011; 39(4): 915-24.
[12]
Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res 2021; 11(5): 1913-35.
[13]
Wallmark B. Mechanism of action of omeprazole. Scand J Gastroenterol 1986; 21(sup118): 11-6.
[http://dx.doi.org/10.3109/00365528609090881] [PMID: 3014640]
[14]
Pawar SK, Punith R, Naik RS, Seetharamappa J. Spectroscopic and molecular modeling approaches to investigate the binding of proton pump inhibitors to human serum albumin. J Biomol Struct Dyn 2017; 35(15): 3205-20.
[http://dx.doi.org/10.1080/07391102.2016.1251337] [PMID: 27771990]
[15]
Lin MZ, Chai WM, Ou-Yang C, Huang Q, Xu XH, Peng YY. Antityrosinase mechanism of omeprazole and its application on the preservation of fresh-cut Fuji apple. Int J Biol Macromol 2018; 117: 538-45.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.05.172] [PMID: 29803745]
[16]
Cartee NMP, Wang MM. Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS One 2020; 15(9): e0239464.
[http://dx.doi.org/10.1371/journal.pone.0239464] [PMID: 32946534]
[17]
Jin UH, Michelhaugh SK, Polin LA, Shrestha R, Mittal S, Safe S. Omeprazole inhibits glioblastoma cell invasion and tumor growth. Cancers 2020; 12(8): 2097.
[http://dx.doi.org/10.3390/cancers12082097] [PMID: 32731514]
[18]
Feng S, Qiu G, Yang L, et al. Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation. Biosci Rep 2021; 41(1): BSR20200842.
[http://dx.doi.org/10.1042/BSR20200842] [PMID: 33393595]
[19]
Li Y, Ren B, Li H, Lu T, Fu R, Wu Z. Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation. Acta Pharmacol Sin 2022; 43(7): 1816-28.
[http://dx.doi.org/10.1038/s41401-021-00787-1] [PMID: 34785782]
[20]
Goel S, Bergholz JS, Zhao JJJNRC. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 2022; 22(6): 356-72.
[http://dx.doi.org/10.1038/s41568-022-00456-3]
[21]
Said MA, Abdelrahman MA, Abourehab MA, Fares M. A patent review of anticancer CDK2 inhibitors (2017–present). Expert Opin Ther Pat 2022; 32(8): 885-98.
[22]
McInnes C, Wang S, Anderson S, O’Boyle J, Jackson W, Kontopidis G, et al. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol 2004; 11(4): 525-34.
[http://dx.doi.org/10.1016/j.chembiol.2004.03.022]
[23]
Echalier A, Hole AJ, Lolli G, Endicott JA. An inhibitor’s-eye view of the ATP-binding site of CDKs in different regulatory states. ACS Chem Biol 2014; 9(6): 1251-6.
[24]
Subramanian J, Sharma S. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases. J Med Chem 2006; 49(18): 5434-41.
[25]
Nazir Y, Rafique H, Roshan S, Shamas S, Ashraf Z, Rafiq M, et al. Molecular docking, synthesis, and tyrosinase inhibition activity of acetophenone amide: Potential inhibitor of melanogenesis. BioMed Res Int 2022; 2022: 1040693.
[26]
Silva LB, Ferreira EFB, Maryam , et al. Galantamine based novel acetylcholinesterase enzyme inhibitors: A molecular modeling design approach. Molecules 2023; 28(3): 1035.
[http://dx.doi.org/10.3390/molecules28031035] [PMID: 36770702]
[27]
Tseng PS, Ande C, Moremen KW, Crich DJAC. Influence of side chain conformation on the activity of glycosidase inhibitors. Angew Chem Int Ed Engl 2023; 62(8): e202217809.
[28]
Ahmed MC, Crehuet R, Lindorff-Larsen KJIDPM. Computing, analyzing, and comparing the radius of gyration and hydrodynamic radius in conformational ensembles of intrinsically disordered proteins. Methods Mol Biol 2020; 2141: 429-5.
[29]
Ittisoponpisan S, Islam SA, Khanna T, Alhuzimi E, David A. Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated? J Mol Biol 2019; 431(11): 2197-212.
[30]
Bai Y, Zhu P, Zhou K, Zhang S-GJE, Medicine T. Effect of the acid suppressor omeprazole on the proliferation, migration, invasion and cell cycle of esophageal squamous cell carcinoma cells via the aryl hydrocarbon receptor pathway. Exp Ther Med 2021; 22(4): 1187.
[http://dx.doi.org/10.3892/etm.2021.10621]
[31]
Hou Y, Hu Q, Huang J. Omeprazole inhibits cell proliferation and induces G0/G1 cell cycle arrest through up-regulating miR-203a-3p expression in Barrett’s esophagus cells. Front Pharmacol 2018; 8: 968.
[32]
Mir MA, Javeed T. Novel CDK inhibitors in breast cancer. In: Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Singapore: Springer 2023; pp. 253-67.
[http://dx.doi.org/10.1007/978-981-19-8911-7_12]

Rights & Permissions Print Cite
Article Metrics
5
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy